Background: The prevalence of chronic kidney disease (CKD) correlates with the prevalence of hypertension (HT). We studied the prevalence and predictors of CKD in a representative sample of the Romanian adult population. Methods: A sample of 1470 subjects were enrolled in the SEPHAR IV (Study for the Evaluation of Prevalence of Hypertension and Cardiovascular Risk) survey. All subjects were evaluated for blood pressure (BP) and extensive evaluations of target organ damage, blood, and urine samples were undertaken. Results: A total of 883 subjects were included in the statistical analysis. Those experiencing CKD with an eGFR < 60 mL/min/1.73 m2 were older at 71.94 ± 7.4 years (n = 19, 2.15%) compared with those without renal impairment at 50.3 ± 16.21 years (n = 864, 97.85%), p < 0.0001. The prevalence of CKD among hypertensives (379 from 883) was 4.49% (17/379), while 17 out of 19 subjects with CKD had HT (89.47%). After adjusting for age, sex, and diabetic status, only serum uric acid (SUR) > 6.9 mg/dL (OR: 6.61; 95% CI: 2.063, 10.83; p = 0.004) was an independent risk factor and a predictor of CKD. Conclusions: The prevalence of CKD in hypertensive Romanian adults was more than ten times higher than in the normotensive population. Levels of SUR > 6.9 mg/dL were predictors of CKD.
Background Data regarding cardiac damage in Romanian hypertensive adults are scarce. Our aim was to assess hypertension-mediated subclinical and clinical cardiac damage using a post-hoc echocardiographic analysis of a national epidemiological survey. Methods A representative sample of 1477 subjects was included in the SEPHAR IV (Study for the Evaluation of Prevalence of Hypertension and Cardiovascular Risk in an Adult Population in Romania) survey. We retrieved echocardiographic data for 976 subjects, who formed our study group. Cardiac damage included left ventricular (LV) hypertrophy (defined as an LV mass > 95 g/m2 in females and > 115 g/m2 in males), coronary artery disease (CAD), and LV diastolic and systolic dysfunction. Results Hypertension prevalence was 46.0% in SEPHAR IV and 45.3% in our study subgroup. Hypertensives had a higher prevalence of LV hypertrophy, CAD, diastolic dysfunction (p<0.001 for all) and systolic dysfunction (p=0.03) than normotensives. Age (OR=1.05;95% CI,1.03–1.08;p<0.001), female sex (OR=2.07;95% CI,1.24–3.45;p=0.006), and systolic blood pressure (OR=1.02;95% CI,1.01−1.04;p=0.026) were independent predictors of LVH in hypertensives. Age was a predictor of diastolic dysfunction (OR=1.04;95% CI,1.02−1.06;p<0.001), and female sex was a protective factor against systolic dysfunction (OR=0.26;95% CI,0.10–0.71;p=0.009). Age (OR=1.05;95% CI,1.02−1.07;p<0.001) and dyslipidemia (OR=1.89;95% CI,1.20–3.00;p=0.007) were independent determinants of CAD in hypertensives. Conclusion The prevalence of cardiac damage in Romanian hypertensives is high. Both non-modifiable risk factors (such as age and gender) and modifiable (such as dyslipidemia and systolic blood pressure) risk factors are independent predictors of cardiac damage in hypertensives.
Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Romanian Ministry of National Education, CNCS-UEFISCDI. Background Atrial fibrillation (AF) is the most frequent arrhythmia in hypertrophic cardiomyopathy (HCM), with a major impact on overall survival, thromboembolic risk, and quality of life. Early recognition and treatment of AF are essential to improve the outcome of HCM patients (pts). Despite the existence of several independent predictors of AF development, the identification of HCM pts at risk for AF is still inconsistent. The identification, quantification, and interpretation of the relationships between different clinical and imaging-derived variables may lead to improved risk stratification and prognosis. Predictive models based on machine learning (ML) could reduce variability while providing useful new medical knowledge. Purpose Develop a ML model (emerging from the integration of clinical and echocardiographic data) capable of accurately detecting HCM pts with AF. Methods A comprehensive clinical and echocardiographic assessment was performed in 151 consecutive pts (52±16 years, 72 men) with HCM, in sinus rhythm. Pts were divided into two groups according to the presence (38 pts) or absence (113 pts) of documented paroxysmal AF (24/48 h ambulatory ECG recordings). 81 features (clinical and echocardiographic parameters) were considered as input to the ML models. Four different ML models were evaluated: Deep Learning (DL), Linear Logistic Regression (LLR), Support Vector Machine (SVM) and Random Forest (RF). Ensemble learning and four-fold cross-validation were employed in all experiments. For each experiment the training dataset was augmented and balanced using the Synthetic Minority Over-sampling Technique. The models were fine-tuned using the following hyper-parameters: learning rate, batch size, number of hidden layers, and number of features used as input. The features were first ranked using the Recursive Feature Elimination method, and the top N features were selected during the hyper-parameter tuning. Results Each ML model was trained for 100 epochs, and the results were extracted from the epoch that led to the best results when combining all four folds. DL was the best performing model, with a learning rate of 0.01, a batch size of 32, 4 hidden layers (256/128/128/64 neurons), and 15 input features. The DL model had 5% higher accuracy compared to LLR, 10% higher than SVM and 8% higher than RF, with consistently higher sensitivity. The performance of the various models is detailed in the table below. Moreover, the DL model had significantly higher accuracy compared to conventional imaging parameters consistently related to the presence of AF in previous studies, such as maximum LA volume (AUC 0.66, accuracy 59%) or LA strain (AUC 0.61, accuracy 62%). Conclusions The DL based model can detect the presence of paroxysmal AF in patients with HCM with an accuracy of 84% (5% higher than the best classic ML model, and significantly higher than independent conventional imaging parameters).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.